We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacotherapy for Schizophrenic Drug Users - 6

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000281
First Posted: September 21, 1999
Last Update Posted: December 15, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University
  Purpose
The purpose of this study is to evaluate maintenance neuroleptics for Schizophrenic patients who are cocaine abusers.

Condition Intervention Phase
Cocaine-Related Disorders Substance-Related Disorders Shcizophrenia Behavioral: Amantadine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy for Schizophrenic Drug Users

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Drug use
  • Retention
  • Psychological symptoms
  • Schizophrenic symptoms

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000281


Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000281     History of Changes
Other Study ID Numbers: NIDA-09250-6
P50DA009250 ( U.S. NIH Grant/Contract )
P50-09250-6
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: December 15, 2016
Last Verified: December 2016

Keywords provided by Yale University:
anti psychotic agents

Additional relevant MeSH terms:
Disease
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Amantadine
Antiparkinson Agents
Anti-Dyskinesia Agents
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents